Attached files
| file | filename |
|---|---|
| EX-10.62 - EXHIBIT 10.62 - Vyant Bio, Inc. | exh1062njamendlease.htm |
| 10-K - 10-K - Vyant Bio, Inc. | cgix-20171231x10xk.htm |
| EX-32.1 - EXHIBIT 32.1 - Vyant Bio, Inc. | a201710-kex321.htm |
| EX-31.1 - EXHIBIT 31.1 - Vyant Bio, Inc. | a201710-kex311.htm |
| EX-21.1 - EXHIBIT 21.1 - Vyant Bio, Inc. | a201710-kex211.htm |
| EX-10.61 - EXHIBIT 10.61 - Vyant Bio, Inc. | exh1061caamendlease.htm |
| EX-10.60 - EXHIBIT 10.60 - Vyant Bio, Inc. | exh1060sharmarelease.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-191520, 333-191521, 333-196198, 333-205903 and 333-214599) and on Form S-3 (Nos. 333-196374, 333-215284 and 333-218229) of Cancer Genetics, Inc. of our report dated April 2, 2018, relating to the consolidated financial statements of Cancer Genetics, Inc. and Subsidiaries appearing in the Annual Report on Form 10-K of Cancer Genetics, Inc. for the year ended December 31, 2017.
/s/ RSM US LLP
New York, New York
April 2, 2018